Less than 1 min.Read

Kazia Therapeutics: Partners with DFCI to treat rare lymphoma

September 22, 2020

Cancer treatment specialist Kazia Therapeutics (KZA) is teaming up with the U.S. Dana-Farber Cancer Institute (DFCI) to treat a rare type of lymphoma
Kazia’s paxlisib drug will tested against primary central nervous system lymphoma (PCNSL), which is a specific type of cancer of the white blood cells
The trial will also recruit up to 25 patients who have relapsed or refractory PCNSL
Recruitment for the trial is slated for early 2021, and it’s expected to take two years to complete
The Dana-Farber Cancer Institute is a principal teaching affiliate of Harvard Medical School
Shares in Kazia rose in early action but have since settled and are currently trading grey, worth 94 cents each